Loading
companiesCompany
Evopoint Biosciences
Evopoint Biosciences is a China-based biotechnology company running 6 late-stage cancer trials of XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma and prostate cancer.
Also called: Evopoint Biosciences Inc.
Overview
Evopoint Biosciences, based in Suzhou, China, is a biotechnology company. An innovation-focused pharmaceutical company (Chinese name Suzhou Innovent... registered as Suzhou Xinnuowei Pharmaceutical Technology Co.) developing small-molecule and antibody drugs for precision oncology and multi-drug resistant bacterial infections, using in-house small molecule, complex antibody (eMAB) and targeted protein degradation (eGLUE) platforms. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma, prostate cancer, hodgkin lymphoma and pancreatic ductal adenocarcinoma. The largest, NCT06799637 (Study of XNW28012 in Subjects With Advanced Solid Tumours Who Failed Standard Treatments), plans to enrol 350 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Suzhou, CN
Scorecard
All companies#347of 1244 companies, score 11
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +6
0 approved, 0 in phase 3, 1 earlier, 1 targets, 8 registry studies. Formula on the scorecards page.
Type
Website
Phase 2small molecule (structure undisclosed or not yet in PubChem)
XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.
Similar pages
- CollectionLymphoma Research Foundation (LRF)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- CompanyHaihe Biopharma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma, Ovarian cancer.
- InstitutionLymphoma Action
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionAnthony Nolan
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- TermVaccinations around lymphoma treatment: the ones to have first, and the ones not to have at all
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- InstitutionBlood Cancer UK
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- TermFertility preservation before lymphoma treatment: a decision with a deadline in days
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma.
- TermCentral venous access (port, PICC line)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma, Hodgkin lymphoma, Pancreatic ductal adenocarcinoma.
cancers
drugs
Phase 2small molecule (structure undisclosed or not yet in PubChem)
trials
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaA Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard TreatmentClinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaClinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer